Trans-arterial Embolization for the Treatment of Facet Pain Due to Facet Arthropathy
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-85
SponsorNorthwell Health
About this trial
This single-site, single-arm study evaluates the feasibility, safety, tolerability, and efficacy of trans-arterial embolization (TAE) using Embozene microparticles for treating facetogenic pain due to facet arthropathy (osteoarthritis of the facet joints) in the lumbar spine.
Eligibility criteria
Qualifiers
Age 18-85
Confirmed diagnosis of spinal facet arthropathy on MRI OR CT
Confirmed diagnosis of lumbosacral facetogenic pain based on diagnostic nerve blocks.
Failed medical management of pain.
Disqualifiers
- Pregnancy
History of prior spinal embolization at the target level.
History of surgery/ stenting of the aorta at the level of embolization.
Severe allergic reaction to iodinated contrast (i.e. anaphylaxis)
Trial design
Treatments tested in this trial
- Spinal angiography and embolization/ Embozene Microspheres
Treatment groups
40 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov